Roivant Q3 loss $208.9M; cash $5.2B; launches brepocitinib Ph2 in sarcoidosis

Roivant Sciences Ltd.

2024-Q3 EPS reported $0.05 revenue$21,483,000

Revenue $9.0M (-42% YoY); loss from continuing ops $208.9M vs. $5.1B income in prior year (Telavant gain).
Cash and marketable securities $5.2B at Dec 31; plus $75M VTAMA milestone and $113M from Immunovant private placement.
New brepocitinib Phase 2 in cutaneous sarcoidosis; topline data expected H2 2026.
Batoclimab pivotal trial results in MG and CIDP expected by March 31, 2025; IMVT-1402 pivotal trials initiated in GD and D2T RA.
LNP litigation vs. Moderna: summary judgment Q2/Q3 2025, jury trial Sept 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.